Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Hepatic Encephalopathy Market Set for Growth at a 1.2% CAGR Through 2036, Driven by Emerging Therapies and Rising Disease Burden | DelveInsight

globenewswire.com
VNDA Vedanta Biosciences' drug VE303 is in Phase II trials for hepatic encephalopathy. The article highlights emerging therapies as a key growth driver for the market, suggesting positive potential for companies like Vedanta Biosciences. GRFS Grifols, S.A. is mentioned for its 25% IV albumin as an emerging therapy for hepatic encephalopathy. The article notes its inclusion in the market growth drivers, but provides no specific details on its performance or outlook. BHC Bausch Health is listed as a company developing drugs for hepatic encephalopathy. However, the article provides no specific details on their pipeline or market impact, leading to a neutral sentiment. RDHL RedHill Biopharma is mentioned in the context of Crohn's Disease, not directly for hepatic encephalopathy. The article focuses on the HE market, making the sentiment for RedHill neutral due to lack of specific HE-related information. MRK Merck is listed as a company in the Crohn's Disease market. As the article's primary focus is hepatic encephalopathy, Merck's sentiment is neutral due to the absence of specific information regarding their involvement in the HE market. TEVA Teva Pharmaceutical is mentioned in the context of Crohn's Disease. The article's main subject is hepatic encephalopathy, thus Teva's sentiment is neutral as no specific HE-related activities are detailed. PFE Pfizer is listed as a company involved in the Crohn's Disease market. Given the article's focus on hepatic encephalopathy, Pfizer's sentiment is neutral due to a lack of specific information regarding their HE pipeline or market presence. SNY Sanofi is mentioned in relation to Crohn's Disease. The article's primary focus is hepatic encephalopathy, so Sanofi's sentiment is neutral due to the absence of specific details about their involvement in the HE market. LLY Eli Lilly is listed as a company in the Crohn's Disease market. The article's main focus is hepatic encephalopathy, thus Eli Lilly's sentiment is neutral as no specific HE-related activities are detailed. ABBV AbbVie is mentioned in the context of Crohn's Disease. The article's primary focus is hepatic encephalopathy, so AbbVie's sentiment is neutral due to the absence of specific details about their involvement in the HE market. AZN AstraZeneca is listed as a company in the Crohn's Disease market. The article's main focus is hepatic encephalopathy, thus AstraZeneca's sentiment is neutral as no specific HE-related activities are detailed. CRCT Corcept Therapeutics is mentioned as a company in the Cushing's Disease market. The article's primary focus is hepatic encephalopathy, thus Corcept's sentiment is neutral due to the absence of specific HE-related information. SPRO Sparrow Pharmaceuticals is listed as a company in the Cushing's Disease market. The article's main focus is hepatic encephalopathy, thus Sparrow's sentiment is neutral as no specific HE-related activities are detailed. CRNX Crinetics Pharmaceuticals is mentioned as a company in the Cushing's Disease market. The article's primary focus is hepatic encephalopathy, thus Crinetics' sentiment is neutral due to the absence of specific HE-related information.

Hepatic Encephalopathy Market Set for Growth at a 1.2% CAGR Through 2036, Driven by Emerging Therapies and Rising Disease Burden | DelveInsight New York, USA, May 04, 2026 (GLOBE NEWSWIRE) -- Hepatic Encephalopathy Market Set for Growth at a 1.2% CAGR Through 2036, Driven by Emerging Therapies and Rising Disease Burden | DelveInsight

The hepatic encephalopathy market is expected to witness steady growth over the coming years, driven by the rising prevalence of chronic liver diseases, cirrhosis, and alcohol-related liver disorders worldwide. Increasing awareness about early diagnosis and improved treatment options are further supporting market expansion. Additionally, the launch of emerging therapies such as VE303 (Vedanta Biosciences), YAQ007 (Yaqrit Discovery Ltd), 25% IV albumin (Grifols, S.A.), EBX-102 (EnteroBiotix Limited), GR3027 (Umecrine Cognition AB), and others will further propel the market growth.

Recently published Hepatic Encephalopathy Market Insights report includes a comprehensive understanding of current treatment practices, hepatic encephalopathy emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].

Hepatic Encephalopathy Market Summary

Discover which region dominates HE market @ https://www.delveinsight.com/sample-request/hepatic-encephalopathy-market

Key Factors Driving the Growth of the Hepatic Encephalopathy Market

According to Stuti Mahajan, consulting manager at DelveInsight, the scarcity of approved treatment options for hepatic encephalopathy leaves a notable gap in the current therapeutic landscape, creating ample opportunity for emerging therapies to establish a strong market presence. Mahajan further added that this unmet need opens the door for innovative treatments with improved efficacy, safety, or differentiated mechanisms to gain a competitive advantage and drive future market growth.

Hepatic Encephalopathy Market Analysis

Learn more about the current treatment for hepatic encephalopathy @ Hepatic Encephalopathy Treatment Market

Hepatic Encephalopathy Competitive Landscape

Some of the hepatic encephalopathy drugs under development include VE303 (Vedanta Biosciences), YAQ007 (Yaqrit Discovery Ltd), 25% IV albumin (Grifols, S.A.), EBX-102 (EnteroBiotix Limited), GR3027 (Umecrine Cognition AB), and others.

Yaqrit Discovery Ltd’s YAQ007 (L-ornithine phenylacetate, L-OPA) is an oral ammonia-scavenging therapy that converts ammonia into phenylacetylglutamine, enabling its permanent elimination from the body. Yaqrit plans to begin a Phase IIb/III study of YAQ007 for the outpatient prevention of recurrent overt hepatic encephalopathy. At present, YAQ007 is also under investigation in a Phase II clinical trial for hepatic encephalopathy treatment.

Vedanta Biosciences’ VE303 is an oral, wholly owned, defined bacterial consortium consisting of eight live commensal bacterial strains, developed to prevent recurrent C. difficile infection (rCDI). It is manufactured using pure clonal cell banks to maintain standardized quality and consistency. These strains act by competing with C. difficile for nutrients while generating secondary bile acids and short-chain fatty acids, which help inhibit harmful bacterial growth, reinforce gut barrier function, and lessen intestinal inflammation. Currently, VE303 is being studied in a Phase II clinical trial for the treatment of hepatic encephalopathy.

The anticipated launch of these emerging hepatic encephalopathy therapies are poised to transform the hepatic encephalopathy market landscape in the coming years. As these cutting-edge hepatic encephalopathy therapies continue to mature and gain regulatory approval, they are expected to reshape the hepatic encephalopathy market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.

To know more about new drugs for hepatic encephalopathy in clinical trials, visit @ Hepatic Encephalopathy Medication

Recent Developments in the Hepatic Encephalopathy Market

What is Hepatic Encephalopathy?

Hepatic Encephalopathy is a serious, potentially reversible brain dysfunction that occurs in people with advanced liver disease, most commonly cirrhosis. When the liver is unable to filter toxins from the blood effectively, substances like ammonia accumulate and travel to the brain, disrupting normal neurological function. This can lead to a wide range of symptoms, from mild cognitive changes such as confusion, poor concentration, and sleep disturbances to more severe manifestations like disorientation, abnormal behavior, and even coma in advanced cases. Hepatic encephalopathy is often triggered or worsened by factors such as infections, gastrointestinal bleeding, dehydration, or constipation. Early recognition and treatment are important, as the condition can often be managed and partially reversed by addressing the underlying cause and reducing toxin buildup.

Hepatic Encephalopathy Epidemiology Segmentation

The hepatic encephalopathy epidemiology section provides insights into the historical and current V patient pool and forecasted trends for the leading markets. In the US, a consistently higher number of cases are projected to be reported in the late-onset group. The number of cases of CHE and OHE were nearly 125,000 and 80,000, respectively, in 2025.

The hepatic encephalopathy market report proffers epidemiological analysis for the study period 2022–2036 in the leading markets segmented into:

Download the report to understand emerging therapies in HE pipeline @ Hepatic Encephalopathy Treatment Options

Scope of the Hepatic Encephalopathy Market Report

Discover more about which companies are developing HE drugs @ Hepatic Encephalopathy Clinical Trials

Table of Contents

Related Reports

Hepatic Encephalopathy Clinical Trial Analysis Pipeline

Hepatic Encephalopathy Pipeline Insight – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key hepatic encephalopathy companies, including Vedanta Biosciences, Yaqrit Discovery Ltd, Grifols, S.A., EnteroBiotix Limited, Umecrine Cognition AB, Bausch Health, and others.

Overt Hepatic Encephalopathy Market

Overt Hepatic Encephalopathy Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key overt hepatic encephalopathy companies, including Salix Pharmaceuticals, Bausch Health, Axcella Health, Inc., Umecrine Cognition, Mallinckrodt Therapeutics, Vedanta Biosciences, Patricia Bloom, and others.

Overt Hepatic Encephalopathy Clinical Trial Analysis Pipeline

Overt Hepatic Encephalopathy Pipeline Insight – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key overt hepatic encephalopathy companies, including Salix Pharmaceuticals, Bausch Health, Axcella Health, Inc., Umecrine Cognition, Mallinckrodt Therapeutics, Vedanta Biosciences, Patricia Bloom, and others.

Crohn's Disease Market

Crohn's Disease Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Crohn's disease companies, including RedHill Biopharma, Merck, Teva Pharmaceutical, Pfizer, Agomab Therapeutics, Sanofi, Medibiofarma, Eli Lilly, NImmune, Avobis Bio, Abivax, Roche, Telavant, Mesoblast, Takeda, AstraZeneca, and others.

Cushing's Disease Market

Cushing's Disease Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Cushing's disease Market companies, including Corcept Therapeutics, Sparrow Pharmaceuticals, Crinetics Pharmaceuticals, H. Lundbeck, Stero Therapeutics, and others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.